140 related articles for article (PubMed ID: 34181850)
21. Targeting MALT1 for the treatment of diffuse large B-cell lymphoma.
Seshadri MR; Melnick AM
Leuk Lymphoma; 2022 Apr; 63(4):789-798. PubMed ID: 34783281
[TBL] [Abstract][Full Text] [Related]
22. MALT1 is a critical mediator of PAR1-driven NF-κB activation and metastasis in multiple tumor types.
McAuley JR; Bailey KM; Ekambaram P; Klei LR; Kang H; Hu D; Freeman TJ; Concel VJ; Hubel NE; Lee JL; Klei HB; Cheng J; Sekar P; Bridwell RE; Covic L; Lucas PC; McAllister-Lucas LM
Oncogene; 2019 Dec; 38(49):7384-7398. PubMed ID: 31420608
[TBL] [Abstract][Full Text] [Related]
23. Discovery of Potent, Highly Selective, and
Pissot Soldermann C; Simic O; Renatus M; Erbel P; Melkko S; Wartmann M; Bigaud M; Weiss A; McSheehy P; Endres R; Santos P; Blank J; Schuffenhauer A; Bold G; Buschmann N; Zoller T; Altmann E; Manley PW; Dix I; Buchdunger E; Scesa J; Quancard J; Schlapbach A; Bornancin F; Radimerski T; Régnier CH
J Med Chem; 2020 Dec; 63(23):14576-14593. PubMed ID: 33252239
[TBL] [Abstract][Full Text] [Related]
24. AUY922 effectively targets against activated B cell subtype of diffuse large B-cell lymphoma and low-grade lymphoma cells harboring genetic alteration-associated nuclear factor-κB activation.
Tsai HJ; Shih NY; Kuo SH; Cheng AL; Lin HY; Chen TY; Chang KC; Lin SF; Chang JS; Chen LT
Leuk Lymphoma; 2015; 56(9):2674-82. PubMed ID: 25535814
[TBL] [Abstract][Full Text] [Related]
25. MALT1 Phosphorylation Controls Activation of T Lymphocytes and Survival of ABC-DLBCL Tumor Cells.
Gehring T; Erdmann T; Rahm M; Graß C; Flatley A; O'Neill TJ; Woods S; Meininger I; Karayel O; Kutzner K; Grau M; Shinohara H; Lammens K; Feederle R; Hauck SM; Lenz G; Krappmann D
Cell Rep; 2019 Oct; 29(4):873-888.e10. PubMed ID: 31644910
[TBL] [Abstract][Full Text] [Related]
26. Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma.
Nagel D; Bognar M; Eitelhuber AC; Kutzner K; Vincendeau M; Krappmann D
Oncotarget; 2015 Dec; 6(39):42232-42. PubMed ID: 26540570
[TBL] [Abstract][Full Text] [Related]
27. MALT1 is a potential therapeutic target in glioblastoma and plays a crucial role in EGFR-induced NF-κB activation.
Liu X; Yue C; Shi L; Liu G; Cao Q; Shan Q; Wang Y; Chen X; Li H; Wang J; Gao S; Niu M; Yu R
J Cell Mol Med; 2020 Jul; 24(13):7550-7562. PubMed ID: 32452133
[TBL] [Abstract][Full Text] [Related]
28. Biperiden and mepazine effectively inhibit MALT1 activity and tumor growth in pancreatic cancer.
Konczalla L; Perez DR; Wenzel N; Wolters-Eisfeld G; Klemp C; Lüddeke J; Wolski A; Landschulze D; Meier C; Buchholz A; Yao D; Hofmann BT; Graß JK; Spriestersbach SL; Grupp K; Schumacher U; Betzel C; Kapis S; Nuguid T; Steinberg P; Püschel K; Sauter G; Bockhorn M; Uzunoglu FG; Izbicki JR; Güngör C; El Gammal AT
Int J Cancer; 2020 Mar; 146(6):1618-1630. PubMed ID: 31291468
[TBL] [Abstract][Full Text] [Related]
29. GRK2 suppresses lymphomagenesis by inhibiting the MALT1 proto-oncoprotein.
Cheng J; Klei LR; Hubel NE; Zhang M; Schairer R; Maurer LM; Klei HB; Kang H; Concel VJ; Delekta PC; Dang EV; Mintz MA; Baens M; Cyster JG; Parameswaran N; Thome M; Lucas PC; McAllister-Lucas LM
J Clin Invest; 2020 Feb; 130(2):1036-1051. PubMed ID: 31961340
[TBL] [Abstract][Full Text] [Related]
30. MALT1 and the API2-MALT1 fusion act between CD40 and IKK and confer NF-kappa B-dependent proliferative advantage and resistance against FAS-induced cell death in B cells.
Ho L; Davis RE; Conne B; Chappuis R; Berczy M; Mhawech P; Staudt LM; Schwaller J
Blood; 2005 Apr; 105(7):2891-9. PubMed ID: 15598810
[TBL] [Abstract][Full Text] [Related]
31. Antiapoptotic properties of MALT1 protease are associated with redox homeostasis in ABC-DLBCL cells.
Zhu L; Tang F; Lei Z; Guo C; Song Y; Huang J; Xia X
Mol Carcinog; 2019 Dec; 58(12):2340-2352. PubMed ID: 31556968
[TBL] [Abstract][Full Text] [Related]
32. Optimization of the
Quancard J; Simic O; Pissot Soldermann C; Aichholz R; Blatter M; Renatus M; Erbel P; Melkko S; Endres R; Sorge M; Kieffer L; Wagner T; Beltz K; Mcsheehy P; Wartmann M; Régnier CH; Calzascia T; Radimerski T; Bigaud M; Weiss A; Bornancin F; Schlapbach A
J Med Chem; 2020 Dec; 63(23):14594-14608. PubMed ID: 33216547
[TBL] [Abstract][Full Text] [Related]
33. Combinatorial treatment rescues tumour-microenvironment-mediated attenuation of MALT1 inhibitors in B-cell lymphomas.
Shah SB; Carlson CR; Lai K; Zhong Z; Marsico G; Lee KM; Félix Vélez NE; Abeles EB; Allam M; Hu T; Walter LD; Martin KE; Gandhi K; Butler SD; Puri R; McCleary-Wheeler AL; Tam W; Elemento O; Takata K; Steidl C; Scott DW; Fontan L; Ueno H; Cosgrove BD; Inghirami G; García AJ; Coskun AF; Koff JL; Melnick A; Singh A
Nat Mater; 2023 Apr; 22(4):511-523. PubMed ID: 36928381
[TBL] [Abstract][Full Text] [Related]
34. Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Inhibitor as a Novel Therapeutic Tool for Lung Injury.
Fusco R; Siracusa R; D'Amico R; Cordaro M; Genovese T; Gugliandolo E; Peritore AF; Crupi R; Di Paola R; Cuzzocrea S; Impellizzeri D
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33092214
[TBL] [Abstract][Full Text] [Related]
35. A MALT1 inhibitor suppresses human myeloid DC, effector T-cell and B-cell responses and retains Th1/regulatory T-cell homeostasis.
Dumont C; Sivars U; Andreasson T; Odqvist L; Mattsson J; DeMicco A; Pardali K; Johansson G; Yrlid L; Cox RJ; Seeliger F; Larsson M; Gehrmann U; Davis AM; Vaarala O
PLoS One; 2020; 15(9):e0222548. PubMed ID: 32870913
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological inhibition of MALT1 protease activity suppresses endothelial activation via enhancing MCPIP1 expression.
Li Y; Huang S; Huang X; Li X; Falcon A; Soutar A; Bornancin F; Jiang Z; Xin HB; Fu M
Cell Signal; 2018 Oct; 50():1-8. PubMed ID: 29913212
[TBL] [Abstract][Full Text] [Related]
37. Targeting Non-proteolytic Protein Ubiquitination for the Treatment of Diffuse Large B Cell Lymphoma.
Yang Y; Kelly P; Shaffer AL; Schmitz R; Yoo HM; Liu X; Huang DW; Webster D; Young RM; Nakagawa M; Ceribelli M; Wright GW; Yang Y; Zhao H; Yu X; Xu W; Chan WC; Jaffe ES; Gascoyne RD; Campo E; Rosenwald A; Ott G; Delabie J; Rimsza L; Staudt LM
Cancer Cell; 2016 Apr; 29(4):494-507. PubMed ID: 27070702
[TBL] [Abstract][Full Text] [Related]
38. Profiling the activity of the para-caspase MALT1 in B-cell acute lymphoblastic leukemia for potential targeted therapeutic application.
Safa FM; Rasmussen T; Fontan L; Xia M; Melnick A; Wiestner A; Lobelle-Rich P; Burger JA; Mouawad Y; Safah H; Flemington EK; Saba NS
Haematologica; 2024 May; 109(5):1348-1358. PubMed ID: 37767562
[TBL] [Abstract][Full Text] [Related]
39. Establishment and characterization of a MALT lymphoma cell line carrying an API2-MALT1 translocation.
Izumi K; Nishikori M; Yuan H; Otsuka Y; Nakao K; Takaori-Kondo A
Genes Chromosomes Cancer; 2020 Sep; 59(9):517-524. PubMed ID: 32348592
[TBL] [Abstract][Full Text] [Related]
40. In silico study of polyphenols as potential inhibitors of MALT1 protein in non-Hodgkin lymphoma.
Sezer A; Mahmutović L; Akçeşme B
Med Oncol; 2023 Dec; 41(1):37. PubMed ID: 38155268
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
